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Removal of the fucose residue from the N-glycans of the Fc portion of immunoglobulin G (IgG)
results in a dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC) through
improved afﬁnity for Fcc receptor IIIa (FccRIIIa). Here, we present the 2.2-A ˚ structure of the
complex formed between nonfucosylated IgG1-Fc and a soluble form of FccRIIIa (sFccRIIIa)
with two N-glycosylation sites. The crystal structure shows that one of the two N-glycans of
sFccRIIIa mediates the interaction with nonfucosylated Fc, thereby stabilizing the complex.
However, fucosylation of the Fc N-glycans inhibits this interaction, because of steric hindrance,
and furthermore, negatively affects the dynamics of the receptor binding site. Our results offer a
structural basis for improvement in ADCC of therapeutic antibodies by defucosylation.
Introduction
The therapeutic applications of antibodies pioneered
by von Behring & Kitasato (1890) at the end of the
19th century were revolutionized by the advent of
monoclonal antibody technology, and subsequently,
improved by genetic engineering approaches such
as humanization (Mayforth 1993). To date, over 20
recombinant monoclonal antibodies have been
licensed as drugs against various cancers and chronic
diseases. Furthermore, antibody-based therapeutics
currently account for most recombinant proteins in
clinical use, and over 130 human monoclonal anti-
bodies entered clinical trials between 2001 and 2008
(Pavlou & Belsey 2005; Reichert et al. 2005).
Although the demand for industrial production of
recombinant monoclonal antibodies is increasing, and
the number of approved antibodies for therapeutic uses
will increase during the next few years, one drawback
of antibody medicine is the high cost of production.
Production costs impose an economic limit on the
therapeutic beneﬁt of these approaches. Recently, a
key breakthrough in the development of therapeutic
antibodies has been achieved that may dramatically
enhance effector functions through a cellular engineer-
ing technique for modifying the sugar chains displayed
on the Fc region of immunoglobulin G (IgG) (Uman ˜a
et al. 1999; Kaneko et al. 2006; Jefferis 2009; Kubota
et al. 2009; Yamane-Ohnuki & Satoh 2009).
The Fc region of IgG possesses a conserved glyco-
sylation site at Asn-297 in each of the CH2 domains.
The N-linked oligosaccharides expressed at this site
are the biantennary complex type with microhetero-
geneities, resulting from the presence or absence of
the nonreducing terminal residues, and they have a
signiﬁcant effect on the effector functions of IgG
(Fig. 1A) (Burton & Woof 1992; Jefferis et al. 1998;
Yamaguchi et al. 2006, 2007). With regard to the
clinical applications of glycoengineered antibodies, the
removal of the core fucose residue from the N-gly-
cans of IgG-Fc results in dramatic enhancement
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1071(>50-fold) of antibody-dependent cellular cytotoxicity
(ADCC) through improved IgG binding to Fcc
receptor IIIa (FccIIIa) (Shields et al. 2002; Shinkawa
et al. 2003; Taniguchi et al. 2006; Kubota et al. 2009;
Yamane-Ohnuki & Satoh 2009). Indeed, a phase I
trial of a defucosylated humanized anti-CC chemokine
receptor 4 (CCR4) antibody, KW-0761, in relapsed
CCR4-positive adult T-cell leukemia–lymphoma or
other peripheral T-cell lymphomas revealed that the
antibody had antilymphoma activity even at a low
dose of 0.01 mg⁄kg (Niwa et al. 2004). Our crystallo-
graphic data on uncomplexed IgG1-Fc fragments
indicated that the overall structures of the fucosylated
and nonfucosylated human IgG1-Fc glycoforms are
quite similar except for the hydration mode around
Tyr-296 (Matsumiya et al. 2007). The crystal struc-
tures of the Fc–FccRIIIb complexes have been
reported for fucosylated IgG1-Fc and the soluble
form of FccRIIIb (sFccRIIIb), which was expressed
in Escherichia coli, and therefore not glycosylated
(Sondermann et al. 2000; Radaev et al. 2001). The
extracellular domains of FccRIIIa possess ﬁve N-gly-
cosylation sites at positions 38, 45, 74, 162, and 169
(Ravetch & Perussia 1989). Mutational deglycosyla-
tion analyses showed that the N-glycan expressed at
Asn-162 has negative and positive effects on the
binding afﬁnities of the fucosylated and nonfucosylat-
ed IgG glycoforms, respectively (Ferrara et al. 2006;
Shibata-Koyama et al. 2009). To gain detailed knowl-
edge of the mechanisms underlying the improvement
in ADCC on defucosylation, it is necessary to obtain
detailed structural information on the interaction
between nonfucosylated IgG and sFccRIIIa possessing
this N-glycan.
Results
Overall structure of Fc–sFccRIIIa complex
We solved the crystal structure of the nonfucosylated
glycoform of human IgG1-Fc complexed with human
sFccRIIIa glycosylated only at Asn-45 and Asn-162
(Fig. 1B). N-glycosylations at these two sites have
been reported to be the minimal requirement for the
expression of sFccRIIIa without proteolytic degrada-
tion in mammalian cells (Shibata-Koyama et al. 2009).
The Fc fragment was cleaved from the nonfucosylated
IgG1 produced in the Fut8
)⁄) cell line Ms704 (Mats-
umiya et al. 2007) by papain digestion, whereas the
bis-glycosylated sFccRIIIa was expressed in the
CHO⁄DG44 cell line with the Asn-to-Gln mutation
of the remaining glycosylation sites (Shibata-Koyama
et al. 2009) and treated with sialidase, resulting in
homogeneous glycosylation with a biantennary
fucosylated complex-type oligosaccharide (Fig. 1A).
The crystal structure of nonfucosylated Fc complexed
with the bis-glycosylated sFccRIIIa was determined
by a molecular replacement technique with the crystal
Figure 1 Structure of nonfucosylated Fc complexed with
bis-glycosylated soluble form of Fcc receptor IIIa (sFccRIIIa).
(A) N-glycans expressed on immunoglobulin G (IgG)-Fc and
sFccRIIIa used for crystallization. Sugar residues that gave
interpretable electron densities are surrounded by solid poly-
gons in Fc-Asn-297 N-glycans and sFccRIIIa-Asn-162 N-gly-
can, whereas those in the sFccRIIIa-Asn-162 N-glycan are
indicated by a dashed box. (B) Overall view of the complex.
Chains A and B of Fc are cyan and pink, respectively, and
sFccRIIIa is yellow. Carbohydrates are shown in sphere repre-
sentation. F, Fuc, fucose; G, Gal, galactose; GN, GlcNAc,
N-acetylglucosamine; M, Man, mannose.
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1072structure of a human fucosylated IgG1-Fc fragment
complexed with nonglycosylated FccRIIIb (PDB ID
code 1E4K) (Sondermann et al. 2000) and reﬁned to
2.2-A ˚ resolution (Table 1).
The overall structure of the present Fc–sFccRIIIa
complex is similar to previously reported crystal struc-
tures of the complexes formed between glycosylated
Fc and nonglycosylated sFccR IIIb (1E4K, 1T83, and
1T89) (Radaev et al. 2001; Sondermann et al. 2000;
Fig. S1 in Supporting Information): The hinge region
and both CH2 domains are involved in the interac-
tion with the D2 domain of sFccRIIIa, and Fc
undergoes a conformational change to adopt a slightly
more open conformation. The electron density of the
N-glycans linked to Fc was well deﬁned and enabled
us to locate eight sugar residues (GlcNAc-1, Glc-
NAc-2, Man-3, Man-4, Man-4¢, GlcNAc-5, Glc-
NAc-5¢, and Gal-6¢) on Fc chains A and B (Fig. 1).
In the case of sFccRIIIa, electron densities of three
(GlcNAc-1, GlcNAc-2, and Man-3) and eight (Fuc,
GlcNAc-1, GlcNAc-2, Man-3, Man-4, Man-4¢, Glc-
NAc-5, and GlcNAc-5¢) sugar residues were observed
in the N-glycans displayed at Asn-45 and Asn-162,
respectively (Fig. 1).
Fc–sFccRIIIa interface
The present crystal structure exhibits a contact surface
area of 1218 A ˚ 2, which is larger than those observed
in the previously reported crystal structures of the
complexes formed between fucosylated Fc and non-
glycosylated sFccRIIIb (876 A ˚ 2 in 1E4K, 887 A ˚ 2 in
1T83, and 800 A ˚ 2 in 1T89). In the present crystal
structure, the surface areas occupied by the carbohy-
drate moieties and the protein portion of the Fc are
261 and 957 A ˚ 2, respectively. The sFccRIIIa-binding
sites consist of the lower hinge, B strand, loop B⁄C,
loop D⁄E, and loop F⁄G of Fc chain A as well as the
lower hinge, B strand, and loop F⁄G of Fc chain B
(Table 2).
On the receptor side, the Fc contact surface is com-
posed of the loops located in the D2 domain. Although
the D1 domain of sFccRIIIa makes little direct con-
tacts with Fc, the carbohydrate chain linked to Asn-45
is oriented toward the CH2 domain of Fc chain B
(Table 2). Interestingly, the N-glycan at Asn-162 inter-
acts with the Fc N-glycans, particularly those of chain
A, through hydrogen bonds and van der Waals contacts
(Fig. 2). The carbohydrate–carbohydrate interaction
occupies approximately 12% (145 A ˚ 2) of the total
interface area.
The present crystal structure also shows that the
aromatic ring of Tyr-296 of Fc chain A is ﬂipped out
and forms a hydrogen bond and van der Waals con-
tacts with Man-4 of the Asn-162 N-glycan as well as
Lys-128 of sFccRIIIa (Fig. 3), thereby stabilizing the
complex. Surface plasmon resonance (SPR) data con-
sistently indicated that alanine substitution of Tyr-296
resulted in impaired afﬁnity for sFccRIIIa in both
fucosylated and nonfucosylated IgG1 glycoforms
(Fig. S2 in Supporting Information). In the previously




Wavelength (A ˚) 0.900
Resolution (A ˚) 87.6–2.20 (2.24–2.20)
Space group P41212
Cell dimensions (A ˚) a = b = 77.3, c = 350.3
Number of observations 673 587
Number of unique reﬂections 53 300
Redundancy 12.6 (6.9)
Completeness (%) 96.4 (77.4)
Mean I⁄r (I) 20.5 (5.9)
Rmerge (%) 0.089 (0.372)
Reﬁnement statistics
Resolution (A ˚) 43.8–2.20











Bond lengths (A ˚) 0.007
Bond angles ( ) 1.03
Ramachandran plot statistics
Most favored (%) 90.5
Additional allowed (%) 8.9
Generously allowed (%) 0.6
Disallowed (%) 0
Values in parentheses are given for the highest resolution shell.
Rmerge = R|Ij)<I>|⁄RIj, where Ij is the intensity of an
individual reﬂection and <I> is the average intensity of
the reﬂection. Rwork = R||Fo|)|Fc||⁄R|Fo|, where Fc is
the calculated structure factor. Rfree is as for Rwork, but
calculated for a randomly selected 5.0% of reﬂections not
included in the reﬁnement. sFccRIIIa, soluble form of Fcc
receptor IIIa.
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1073reported crystal structures of fucosylated Fc and non-
glycosylated sFccRIIIb (i.e., 1E4K, 1T83, and 1T89),
the D⁄E loop of Fc chain A, which contains this
tyrosine residue, exhibits two alternate conformations.
In one crystal structure (1T83), which bears the
closest resemblance in overall structure to the present
structure, the Tyr-296 aromatic ring is also ﬂipped
out, interacting with Lys-128 of sFccRIIIb. In the
remaining crystal structures (1E4K and 1T89), this
tyrosine ring makes intramolecular contacts with the
core fucose residue and turns away from sFccRIII.
These data suggest that Fc and sFccRIII have two
binding modes with high and low afﬁnities, depend-
ing on the orientation of the aromatic ring of
Tyr-296 (Fig. 3).
Involvement of carbohydrate moieties in
Fc–sFccRIIIa interactions
To assess the importance of the observed carbo-
hydrate–carbohydrate interactions, we investigated the
possible effects of enzymatic trimming of the N-gly-
cans of sFccRIIIa on its binding to fucosylated and
nonfucosylated IgG glycoproteins by SPR measure-
ments (Fig. 4). The Fc binding afﬁnity slightly
increased on the removal of the outer lactosamine
branches of the sFccRIIIa N-glycans, although Glc-
NAc-5 of the Asn-162 N-glycan positively interacts
with Man-4¢ and Arg-301 of Fc chain A, at least in
the case of its nonfucosylated glycoform (Fig. 2B,C).
This afﬁnity enhancement can be ascribed to the
removal of the outer carbohydrate branches of the
N-glycan at Asn-45, which are in close spatial prox-
imity to the CH2 domain of Fc chain B and may
cause steric hindrance, although their electron
densities are not interpretable (Fig. 5A). Mutational
deglycosylation at Asn-45 was reported to enhance
the afﬁnity for Fc (Shibata-Koyama et al. 2009).
The removal of GlcNAc-2 and the trimannosyl
parts of the sFccRIIIa N-glycans (i.e., Man-3, Man-
4, and Man-4¢) have more pronounced positive and
negative effects on the interactions with fucosylated
and nonfucosylated Fc glycoforms, respectively
(Fig. 4). These data are consistent with previously
reported mutational deglycosylation data (Ferrara et al.
2006; Shibata-Koyama et al. 2009), as well as the
present crystal structure in which these sugar residues
show productive contacts with Tyr-296 and the non-
fucosylated GlcNAc-1 residue of Fc chain A. Further-
more, our structural model indicates that fucosylation
of GlcNAc-1 in chain A causes steric hindrance with
GlcNAc-2 and Man-3 of the sFccRIIIa-Asn-162
N-glycan (Fig. 5B), which results in impaired interac-
tion between these two glycoproteins. This explains
why afﬁnity enhancement on the extensive trimming
of the sFccRIIIa N-glycans was selectively observed
in the fucosylated glycoform of Fc.
Table 2 Interactions between immunoglobulin G (IgG)-Fc
and soluble form of Fcc receptor IIIa (sFccRIIIa)


















K128 E294, Q295, Y296, N297,
S298
G129 Y296, N297, S298
R130 S298
K131 E269, H268, S298
Y132 G237, P238, D265, V266,
S267, E269, S298, T299,
GN1
H134 G236, G237, P238, D265,













GN5 R301, GN2, M4¢
GN5¢ Y296
Fuc GN5
The underlined residues are involved in hydrogen-bonding
interactions.
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1074Discussion
Although it is widely recognized that glycosylation of
immune receptors can inﬂuence their afﬁnities for the
cognate ligands (Standley & Baudry 2000), not much
is known about the speciﬁc roles of the individual
glycans from a structural aspect. The present crystallo-
graphic data demonstrated that one of the two N-gly-
cans (Asn162 N-glycan) of sFccRIIIa mediates the
interaction with nonfucosylated Fc, thereby stabilizing
the complex. To the best of our knowledge, this is
the ﬁrst atomic description of the carbohydrate–
carbohydrate interactions that mediate the formation
of complexes between glycoproteins. Fucosylation of
the Fc N-glycans inhibits these positive interactions,
because of steric hindrance, thereby impairing IgG
binding to FccRIIIa and the consequent ADCC
activity. On the other hand, the N-glycan displayed
at Asn-45 of sFccRIII negatively affects its binding to
Fc (Shibata-Koyama et al. 2009), most probably
because of steric clash with the CH2 domain
(Fig. 5A).
Moreover, the present crystal structure, in compar-
ison with those previously reported for the low-afﬁn-
ity complexes, indicates that Fc and sFccRIII have
two binding modes depending on the orientation of
the aromatic ring of Tyr-296 of Fc chain A (Fig. 3).
Our previous NMR data demonstrated that Tyr-296
of the nonfucosylated Fc glycoform exhibits confor-
mational multiplicity in its uncomplexed state (Mats-
umiya et al. 2007), suggesting that conformational
selection is governed by the presence or absence of
the fucose residue of the Fc N-glycan. Fucose deple-
tion increases the incidence of the active conforma-
tion of Tyr-296, and thereby accelerates the
formation of the high-afﬁnity complex. This interpre-
tation is supported by our previous data indicating
that an increase in afﬁnity by defucosylation was pri-
marily ascribed to an enhanced association rate (Oka-
zaki et al. 2004). Consistently, our SPR data show
that sFccRIIIa has higher afﬁnity for the nonfucosy-
lated Fc than for the fucosylated Fc, even after exten-
sive trimming of its N-glycans (Fig. 4).
These data are consistent with previously reported
thermodynamic data indicating that afﬁnity enhance-
ment on defucosylation is characterized by favorable
DH, but opposed by unfavorable DS (Okazaki et al.
2004). The favorable DH can be ascribed, at least
partially, to the productive contacts caused by the
ﬂipping out of the Tyr-296 ring and accommodation
Figure 2 Binding of nonfucosylated Fc to soluble form of Fcc receptor IIIa (sFccRIIIa) is mediated by carbohydrate–protein and
carbohydrate–carbohydrate interactions. (A) Close-up view of the interface between sFccRIIIa-Asn162 N-glycan and the Fc
N-glycans [in chain A (upper panel) and chain B (lower panel)]. Hydrogen bonds are represented by dotted lines. (B) Close-up
view of the interface between the sFccRIIIa-Asn162 N-glycan (yellow) and Fc chain A (cyan) (C) Schematic representation of the
carbohydrate–carbohydrate interactions.
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1075of the sFccRIIIa-Asn-162 N-glycan, both of which
result in conformational entropy loss.
The present crystallographic data provide a structural
basis for the improvement in ADCC on defucosylation
of IgG-Fc through the enhancement of its afﬁnity for
FccRIIIa, thus offering new clues for designing and
engineering antibody medicines with improved efﬁ-
cacy. From a more general viewpoint, this study shows
that the oligosaccharides displayed on proteins can
modulate complex formation, positively and nega-
tively, not only through intermolecular carbohydrate–
protein and carbohydrate–carbohydrate interactions
but also by inﬂuencing protein dynamics coupled with
the selection of protein–protein interaction modes.
Experimental procedures
Preparation of IgG-Fc
The CHO⁄DG44 cell line (Urlaub et al. 1986) was kindly
provided by Dr Lawrence Chasin (Columbia University,
NY). The fucosylated and nonfucosylated forms (designated
KM3060 and KM3416, respectively) of an anti-CCR4 chi-
meric antibody with human IgG1⁄j constant regions along
with their Y296A mutants, constructed using the Quik-
Change
  Multi Site-Directed Mutagenesis kit (Stratagene),
were expressed by the CHO⁄DG44 cell line and the
FUT8
) ⁄ ) cell line Ms704, respectively, as previously
described (Matsumiya et al. 2007). The nonfucosylated and
fucosylated IgG1 glycoproteins were expressed and puriﬁed
as previously described (Yamaguchi et al. 2006; Matsumiya
et al. 2007). The Fc fragments were prepared by papain
digestion as previously described (Yamaguchi et al. 2006),
and the purity of the isolated Fc fragment was examined by
SDS-PAGE.
Preparation of sFccRIIIa
The human sFccRIIIa mutant with two N-glycosylation sites
at Asn-45 and Asn-162 was expressed and puriﬁed as previ-
ously described (Shibata-Koyama et al. 2009). In brief, the
extracellular region of human FccRIIIa with an N-terminal
hexahistidine tag and glutamine substitutions at Asn-38,
Figure 3 Alternative modes of Fc–soluble form of Fcc receptor IIIa (sFccRIIIa) interaction with different orientations of the Tyr-
296 aromatic ring depending on Fc fucosylation. (A) The present crystal structure, in which the aromatic ring of Tyr-296 of non-
fucosylated Fc (chain A) is ﬂipped out and sandwiched between Man-4 of the Asn-162 glycan and Lys-128 of sFccRIIIa. (B) 3D
model of sFccRIIIa bound to fucosylated Fc, in which the tyrosine ring does not make contact with the receptor, but makes intra-
molecular contact with the core fucose residue. The model is based on the crystal structure of the complex between fucosylated Fc
and nonglycosylated sFccRIIIb (1E4K) with substitution of the receptor molecule by bis-glycosylated sFccRIIIb in the present
crystal structure by superposing its D2 domains. In this model, the core fucose residue was attached to GlcNAc-1 by the a1–6 gly-
cosidic linkage in the N-glycans in Fc chain A by superimposing the crystal structure of the fucosylated IgG1-Fc (3AVE). Chains
A and B of Fc are cyan and pink, respectively, and sFccRIIIa is yellow.
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1076Asn-74, and Asn-169 was expressed by the CHO⁄DG44 cell
line as a recombinant protein modiﬁed exclusively with sialy-
lated biantennary N-glycans (Shibata-Koyama et al. 2009). A
series of sFccRIIIa glycoforms were prepared according to the
protocols described below.
1 Sialidase treatment: sFccRIIIa was dissolved in 50 mM
sodium acetate buffer, pH 5.5, and incubated at 37  C for
12 h in the presence of 0.01 units⁄mL a-sialidase (Arthro-
bacter ureafaciens; Nacalai Tesque).
2 Galactosidase treatment: Desialylated sFccRIIIa was dis-
solved in 50 mM sodium acetate buffer, pH 5.5, and incu-
bated at 37  C for 12 h in the presence of 0.006 units⁄mL
of b-galactosidase (Streptococcus pneumoniae, recombinant pro-
tein from E. coli; Calbiochem).
3 N-Acetylhexosaminidase treatment: Degalactosylated
sFccRIIIa (2 mg⁄mL) was dissolved in 50 mM sodium ace-
tate buffer, pH 5.5, and incubated at 37  C for 12 h in the
presence of 0.1 units⁄mL of N-acetylhexosaminidase
(S. pneumoniae, recombinant protein from E. coli; Calbio-
chem).
4 Endo D treatment: Galactosidase- and N-acetylhexosamini-
dase-treated sFccRIIIa (2 mg⁄mL) were dissolved in 50 mM
sodium acetate buffer, pH 5.5, and incubated at 37  C for
12 h in the presence of 0.02 units⁄mL of Endo D (Diplo-
coccus pneumoniae; Seikagaku Kogyo Co.).
In each case, the reaction mixture was neutralized with
1.5 M Tris–HCl (pH 8.0) and then subjected to Ni-NTA
chromatography to purify sFccRIIIa. sFccRIIIa was incubated
under the same conditions in the absence of the corresponding
enzyme(s) to prepare mock-treated controls.
Figure 4 Glycoform-dependent interactions between human
immunoglobulin G1 (IgG1) and soluble form of Fcc receptor IIIa
(sFccRIIIa). (A) Carbohydrate sequence of sFccRIIIa used in the
present study. Dotted arrows indicate cleavage sites of glycosidas-
es. The resulting glycoforms are indicated by arrows. (B) White
and gray bars represent KD values of the binding of sFccRIIIa
glycoforms to nonfucosylated and fucosylated IgG glycoproteins,
respectively. These values were calculated based on SPR data.
Figure 5 Potential steric hindrance effects in interactions between (A) CH2 domain of Fc and soluble form of Fcc receptor IIIa
(sFccRIIIa)-Asn-45 N-glycan and (B) fucosylated N-glycan of Fc chain A and sFccRIIIa-Asn-162 N-glycan. The sugar residues of
the Asn-45 N-glycan gave no interpretable electron density, and the core fucose residues of the Fc N-glycan were modeled and
displayed in red. The modeling was based on the conformations of the N-glycan of Fc chain A (for the lactosamine branches in A)
and the Asn-162 N-glycan (for the fucose residues in A and B).
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1077Glycosylation proﬁling
N-glycosylation proﬁling of Fc and sFccRIIIa was carried out
by the HPLC mapping method on the basis of elution proﬁles of
pyridylamino derivatives of their N-linked oligosaccharides on
Shim-pack HRC-octadecyl silica columns (Shimadzu), as previ-
ously described (Takahashi et al. 2002; Yamaguchi et al. 2006).
Crystallization, data collection, and structure
determination
The nonfucosylated Fc fragment and desialylated sFccRIIIa
mutant were mixed at a molar ratio of 1 : 1 and then applied
to a gel ﬁltration column (Superose 12; GE Healthcare) equili-
brated with 20 mM Tris–HCl buffer, pH 7.5, containing
100 mM NaCl. Fractions containing the Fc–sFccRIIIa complex
were concentrated to a total protein concentration of
20 mg⁄mL and used for crystallization.
Crystals were grown by the sitting-drop vapor-diffusion
method at 20  C by mixing the Fc–sFccRIIIa complex with a
reservoir [0.1 M MES, pH 6.5, 12% (w⁄v) PEG 20000]. Crystals
were soaked in a cryoprotectant solution [0.1 M MES, pH 6.5,
20% (w⁄v) PEG 20000, 15% (v⁄v) glycerol] and ﬂash-frozen.
Diffraction data were collected at 100 K using a wavelength of
0.9 A ˚ on a beamline BL44XU (SPring-8). Data processing and
reduction were carried out using the HKL-2000 software pack-
age (Otwinowski & Minor 1997). The crystals belong to the
space group P41212, with cell dimensions a = b = 77.3 A ˚,
c = 350.3 A ˚ at 2.2-A ˚ resolution. The value of the Matthews
coefﬁcient is 3.34 A ˚ 3⁄Da for one molecule, corresponding to a
solvent content of 63.2%. Data collection, phasing, and reﬁne-
ment statistics are summarized in Table 1. The structure of the
complex between nonfucosylated Fc and bis-glycosylated
sFccRIIIa was determined by molecular replacement using the
structures of the complex between fucosylated Fc and nongly-
cosylated sFccRIIIa (Sondermann et al. 2000) (PDB ID code
1E4K) using MOLREP(CCP4, 1994; Vagin & Teplyakov
1997). The model was furthermore built using the program
COOT (Emsley & Cowtan 2004) and then improved by several
cycles of manual rebuilding and reﬁnement using the program
REFMAC5 (Murshudov et al. 1997). The ﬁnal model contains
the Fc residues 229–443 (chain A) and 229–444 (chain B), and
the sFccRIIIa residues 5–30 and 41–174. Phasing and reﬁne-
ment statistics are summarized in Table 1. There are no residues
in disallowed regions of the Ramachandran plot. Buried surface
area and surface complementarity were calculated using
AREAIMOL (Lee & Richards 1971). SFCHECK and
PROCHECK (CCP4, 1994) were used for structure validation.
Molecular graphics were prepared using PyMOL (DeLano
2002). Atomic coordinates and structure factors have been
deposited in the PDB under accession code 3AY4.
Surface plasmon resonance measurements
Interactions of the sFccRIIIa glycoforms with fucosylated and
nonfucosylated IgG glycoproteins were analyzed by SPR using
the T100 biosensor system (GE Healthcare). Mouse anti-tetra-
His IgG antibody (Qiagen) was immobilized on CM5 bio-
sensor chips by an amine coupling method according to the
manufacturer’s instructions. The individual glycoforms of the
hexa-His-tagged sFccRIIIa glycoproteins were captured by
the immobilized anti-tetra-His antibodies at a ﬂow rate of
5 lL⁄min using HBS-EP+ buffer (10 mM HEPES, 150 mM
NaCl, 3 mM EDTA, and 0.05% v⁄v surfactant P20, pH 7.4) at
25  C. Assays were performed using nonfucosylated and
fucosylated IgG glycoproteins at seven concentrations (ranging
from 4 to 267 nM) in a mobile phase at a ﬂow rate of
30 lL⁄min using the HBS-EP+ buffer at 25  C. The dissocia-
tion constant (KD) was calculated by steady-state afﬁnity analy-
sis using Biacore T100 evaluation software version 2.0.1 (GE
Healthcare). To repeat experiments, sFccRIIIa and human
IgG1 were removed from the sensor tips by injecting 10 mM
glycine–HCl, pH 1.5, at a ﬂow rate of 60 lL⁄min for 1 min.
KD values are the mean ± SD of three independent experi-
ments.
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